e-learning
resources
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
RON tyrosine kinase mutations in brain metastases from lung cancer
Melissa Milan, Silvia Benvenuti, Alice Maria Balderacchi, Anna Rita Virzì, Alessandra Gentile, Rebecca Senetta, Paola Cassoni, Paolo Maria Comoglio, Giulia Maria Stella
Source:
ERJ Open Res, 4 (1) 00083-2017; 10.1183/23120541.00083-2017
Journal Issue:
January
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Melissa Milan, Silvia Benvenuti, Alice Maria Balderacchi, Anna Rita Virzì, Alessandra Gentile, Rebecca Senetta, Paola Cassoni, Paolo Maria Comoglio, Giulia Maria Stella. RON tyrosine kinase mutations in brain metastases from lung cancer. ERJ Open Res, 4 (1) 00083-2017; 10.1183/23120541.00083-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Optimizing invasive ventilation for SMA type 1 children who are receiving the gene therapy
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
EGFR tyrosine kinase inhibitors
versus
chemotherapy in
EGFR
wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017
Year: 2017
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
Source: Eur Respir J 2012; 39: 677-684
Year: 2012
The prediction of risk factors of tyrosine kinase inhibitor-induced pneumonitis in non-small cell lung cancer
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
Source: Eur Respir J 2013; 41: 417-424
Year: 2013
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
Source: Eur Respir J 2011; 37: 624-631
Year: 2011
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
Source: Eur Respir J 2009; 33: 436-440
Year: 2009
Lung adenocarcinoma patients of young age have lower
EGFR
mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016
Year: 2017
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Source: Eur Respir J 2012; 39: 366-372
Year: 2012
CREB signaling in KRAS-driven lung adenocarcinoma
Source: ERS Lung Science Conference 2017
Year: 2017
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
Radiation/cisplatin/vinorelbine therapy increase p53 protein phosphorylated at serine 392 in recurrent primary squamous cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 17s
Year: 2001
Croatian Caucasians with lung adenocarcinoma harbouring EGFR mutations with and without brain metastasis
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017
Nonsmall cell lung cancer
Source: Eur Respir Rev 2013; 22: 33-36
Year: 2013
Prognostic significance and correlation between Akt phosphorylation and loss of PTEN protein expression in non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 458s
Year: 2005
Oncogenic potential of MET SEMA mutations affecting brain metastases from NSCLC is sustained by their microrheological features
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017
K-RAS oncogenic mutations in patients with nonsmall cell lung cancer
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept